Barclays PLC Has $24.79 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS

Barclays PLC boosted its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 354.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 653,830 shares of the company’s stock after acquiring an additional 509,946 shares during the quarter. Barclays PLC owned 0.99% of Mineralys Therapeutics worth $24,793,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Victory Capital Management Inc. acquired a new stake in Mineralys Therapeutics during the 3rd quarter valued at approximately $216,000. American Century Companies Inc. raised its holdings in Mineralys Therapeutics by 5.4% during the 3rd quarter. American Century Companies Inc. now owns 879,682 shares of the company’s stock worth $33,358,000 after purchasing an additional 44,901 shares during the last quarter. Greenland Capital Management LP lifted its position in shares of Mineralys Therapeutics by 958.5% in the 3rd quarter. Greenland Capital Management LP now owns 105,853 shares of the company’s stock worth $4,014,000 after purchasing an additional 95,853 shares during the period. Citigroup Inc. lifted its position in shares of Mineralys Therapeutics by 501.7% in the 3rd quarter. Citigroup Inc. now owns 163,168 shares of the company’s stock worth $6,187,000 after purchasing an additional 136,050 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Mineralys Therapeutics by 29.8% in the 3rd quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company’s stock valued at $114,480,000 after purchasing an additional 692,550 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on MLYS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. HC Wainwright set a $56.00 target price on Mineralys Therapeutics and gave the company a “buy” rating in a research report on Tuesday. Stifel Nicolaus raised their target price on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Finally, Wall Street Zen downgraded Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $47.43.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $27.97 on Thursday. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -9.48 and a beta of 0.57. Mineralys Therapeutics, Inc. has a 52-week low of $10.44 and a 52-week high of $47.65. The company has a 50-day simple moving average of $30.83 and a two-hundred day simple moving average of $35.35.

Insider Buying and Selling

In other news, CEO Jon Congleton sold 16,236 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $32.62, for a total transaction of $529,618.32. Following the transaction, the chief executive officer owned 639,151 shares of the company’s stock, valued at $20,849,105.62. This represents a 2.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Malcom Rodman sold 2,171 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $26.84, for a total transaction of $58,269.64. Following the sale, the insider directly owned 82,489 shares in the company, valued at approximately $2,214,004.76. This trade represents a 2.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 342,919 shares of company stock worth $11,755,439. Insiders own 25.56% of the company’s stock.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.